Immunomedics Inc. said Monday that its humanizedmonoclonal antibody against the cancer markercarcinoembryonic antigen (CEA) successfully targeted aCEA-containing cancer.The one-patient study, performed at the Garden State CancerStudy in Newark, N.J., showed that targeting of thehumanized antibody was comparable to that of the mouseantibody, said Immunomedics spokeswoman, Amy Factor.The genetically engineered antibody targets and binds tocancer cells, delivering a therapeutic radioisotope to destroythe cells."This represents one of several new humanized therapeuticantibodies, attached with cytotoxic radioisotopes, which weare planning to take to clinical trials in diverse cancer types,"said Carl Pinsky, the company¿s vice president of medicalaffairs.The Morris Plains, N.J., company plans a Phase I/II dose-escalating trial of the humanized version to treat lymphoma inabout 15 months, Factor said. The company also plans to taketo trial the humanized monoclonal antibody for colorectalcancer and breast cancer.Jim Shrine
(c) 1997 American Health Consultants. All rights reserved.